Related Experiment Video
Updated: Feb 11, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Transformation to small cell lung cancer after first-line afatinib treatment
Takayuki Shiroyama1, Shingo Nasu1, Ayako Tanaka1
1Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Abstract:
Acquiring resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is inevitable. Transformation to small cell lung cancer (SCLC) is reported as a possible mechanism of this acquired resistance. We describe the case of a 35-year-old man with lung adenocarcinoma harboring EGFR exon 19 deletion. After 7 months of successful treatment with afatinib, he experienced relapse and rebiopsy revealed SCLC with EGFR exon 19 deletion. Tumor marker tests at this point showed normal levels of serum neuron-specific enolase and pro-gastrin releasing peptide. Our case highlights the importance of rebiopsy for revealing SCLC transformation, a potential mechanism of acquired resistance to afatinib as with other EGFR-TKIs, and normal-range values of tumor markers for SCLC cannot exclude the possibility of SCLC transformation.
Insights
Acquired resistance to EGFR-TKIs can occur through transformation to small cell lung cancer (SCLC). Rebiopsy is crucial for diagnosis, even with normal tumor markers, in EGFR-mutated lung adenocarcinoma patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatments for EGFR-mutated lung adenocarcinoma.
- Acquired resistance to EGFR-TKIs is a significant clinical challenge.
- Transformation to small cell lung cancer (SCLC) is a recognized mechanism of acquired resistance.
Observation:
- A 35-year-old male with EGFR exon 19 deletion lung adenocarcinoma developed resistance to afatinib after 7 months.
- Rebiopsy revealed transformation to SCLC, still harboring the EGFR exon 19 deletion.
- Serum neuron-specific enolase and pro-gastrin releasing peptide levels were within normal ranges.
Findings:
- SCLC transformation can occur in EGFR-mutated lung adenocarcinoma despite initial response to EGFR-TKIs.
- EGFR mutations can persist in the SCLC component after transformation.
- Normal tumor marker levels do not rule out SCLC transformation.
Implications:
- Rebiopsy is essential for identifying SCLC transformation as a cause of acquired resistance to EGFR-TKIs.
- This case underscores the importance of considering histological transformation in treatment-resistant EGFR-mutated lung cancers.
- Clinical management strategies may need to adapt to account for SCLC transformation in lung adenocarcinoma.
Related Concept Videos
Treatment Resistant Cancers
Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
Lung Capacity
Transformers
The iron core has a substantial relative permeability. Therefore, the magnetic field lines generated due to the current in one winding are almost entirely confined within the core, such that the same magnetic flux permeates each turn of both...
Transformation
Transformations of Functions I

